The chemistry and pharmacology, pharmacokinetics, pharmacodynamics, adverse effects, drug interactions, dosing and administration, and pharmacoeconomics of bivalirudin are reviewed; clinical ...

The Hirulog and Early Reperfusion or Occlusion (HERO-2) study was a large, randomized, open-label trial that compared bivalirudin with heparin in patients undergoing fibrinolysis with SK for acute MI.

Unfractionated heparin, low-molecular-weight heparin (enoxaparin or fondaparinux) or bivalirudin may be used; unfractionated heparin should be given for 48 hours total and low molecular weight ...